Remedy meds Weight loss Review – Forbes Health
remedy Meds offers access to compounded GLP-1 medications for weight loss, operating on a membership model that bypasses conventional insurance requirements and waitlists. The process begins with a short quiz to determine potential eligibility, followed by a review of the results by a licensed clinician within 24 hours. If deemed appropriate, a video appointment may be scheduled to discuss prescription options.
To ensure patient safety, providers may request recent lab results (within the last two years) or facilitate testing at Quest, BioReference, or LabCorp locations – at no additional cost beyond membership fees. Onc a prescription is approved, a four-week supply of medication typically arrives within seven business days, with tracking information provided via email. Patients are advised to submit a refill request through the patient portal after three weeks to avoid any disruption in delivery.
Remedy Meds does not establish a primary care relationship with patients.Though, access to a care team is included in the monthly membership fee, allowing users to schedule appointments or submit questions through the patient portal at any time.
Eligibility:
While specific eligibility criteria aren’t detailed on the Remedy Meds website, the terms and conditions state individuals must be at least 18 years old. Generally,GLP-1 medications are intended for adults with a Body Mass Index (BMI) of 30 or higher (obesity),or those with a BMI of 27 or higher who also have weight-related health conditions such as high blood pressure,diabetes,or obstructive sleep apnea,according to Raj Dasgupta,M.D., an internist at Huntington Health hospital in Pasadena, California. Dr. Dasgupta cautions against using GLP-1s solely for cosmetic weight loss due to limited safety data in individuals who don’t have a medical need for them.
Contraindications & Potential Side Effects:
Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) syndrome should avoid compounded semaglutide and tirzepatide due to FDA “box warnings” regarding a potential risk of thyroid C-cell tumors.
Common side effects of GLP-1 receptor agonists can include gastrointestinal issues like nausea, vomiting, diarrhea, and constipation, especially when starting treatment. More serious potential side effects include pancreatitis, gallbladder problems, kidney issues, retinal damage (in individuals with diabetes), and intestinal blockage. As compounded medications,these treatments also carry inherent risks.
